Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BON Bon Natural Life	$1.41 +1.4%	$1.38	$1.14 ▼ $73.75	$235K	-0.47	1.73 million shs	35,379 shs
BPTH Bio-Path	$0.12 +23.3%	$0.15	$0.09 ▼ $3.39	$1.03M	-0.06	178,768 shs	54,711 shs
HEPA Hepion Pharmaceuticals	$0.08 +25.6%	$0.06	$0.03 ▼ $0.08	$921K	1.52	91,470 shs	30,763 shs
PBLA Panbela Therapeutics	$0.16	$0.18	$0.05 ▼ $0.47	$767K	1.33	16,242 shs	29,270 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BON Bon Natural Life	0.00%	+6.92%	-0.71%	-12.58%	-96.96%
BPTH Bio-Path	-8.18%	-15.83%	-33.81%	-40.59%	-91.06%
HEPA Hepion Pharmaceuticals	-2.29%	+22.56%	+19.81%	+6.83%	-99.84%
PBLA Panbela Therapeutics	0.00%	0.00%	0.00%	-34.59%	-56.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BPTH Bio-Path	0.812 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	1.3
HEPA Hepion Pharmaceuticals	0.4844 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	0.6
PBLA Panbela Therapeutics	0.262 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
BON Bon Natural Life	N/A	N/A	N/A
BPTH Bio-Path	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BON Bon Natural Life	$23.84M	0.01	$1.81 per share	0.78	$37.78 per share	0.04
BPTH Bio-Path	N/A	N/A	N/A	N/A	$0.71 per share	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.29 per share	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	($18.37) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BON Bon Natural Life	$400K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
BPTH Bio-Path	-$16.08M	N/A	0.00	N/A	N/A	N/A	-2,842.40%	-337.48%	11/13/2025 (Estimated)
HEPA Hepion Pharmaceuticals	-$48.93M	-$219.00	N/A	∞	N/A	N/A	-812.56%	-207.31%	11/12/2025 (Estimated)
PBLA Panbela Therapeutics	-$25.26M	-$71.13	N/A	∞	N/A	N/A	N/A	-302.61%	11/12/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A
BPTH Bio-Path	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BON Bon Natural Life	0.02	2.42	2.32
BPTH Bio-Path	N/A	0.86	0.86
HEPA Hepion Pharmaceuticals	N/A	1.30	1.30
PBLA Panbela Therapeutics	N/A	0.26	0.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BON Bon Natural Life	0.57%
BPTH Bio-Path	5.74%
HEPA Hepion Pharmaceuticals	17.24%
PBLA Panbela Therapeutics	4.37%

Insider Ownership

Company	Insider Ownership
BON Bon Natural Life	26.48%
BPTH Bio-Path	0.72%
HEPA Hepion Pharmaceuticals	0.06%
PBLA Panbela Therapeutics	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BON Bon Natural Life	100	167,000	863,000	Not Optionable
BPTH Bio-Path	10	8.31 million	5.73 million	Optionable
HEPA Hepion Pharmaceuticals	20	11.44 million	6.63 million	No Data
PBLA Panbela Therapeutics	6	4.86 million	4.86 million	Not Optionable

BON, BPTH, PBLA, and HEPA Headlines

Recent News About These Companies

Panbela Therapeutics Announces Q3 2024 Financial Results

November 16, 2024 | markets.businessinsider.com

Panbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2024 Financial Results

November 15, 2024 | finanznachrichten.de

Panbela Therapeutics Inc (PBLA) Q3 2024 Earnings Call Highlights: Strategic Loan and Clinical ...

November 15, 2024 | finance.yahoo.com

Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript

November 14, 2024 | seekingalpha.com

Panbela Provides Business Update and Reports Q3 2024 Financial Results

November 14, 2024 | globenewswire.com

Panbela Therapeutics (OTC:PBLA) Stock, Insider Trading Activity

October 6, 2024 | benzinga.com

Horace Mann Educators (NYSE:HMN) Stock Quotes, Forecast and News Summary

October 5, 2024 | benzinga.com

Panbela Therapeutics (OTC:PBLA) Stock, Short Interest Report

October 5, 2024 | benzinga.com

Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2024 Earnings Call Transcript

August 15, 2024 | insidermonkey.com

Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript

August 14, 2024 | seekingalpha.com

Panbela Provides Business Update and Reports Q2 2024 Financial Results

August 13, 2024 | globenewswire.com

Is Panbela Therapeutics Inc (PBLA) Stock a Good Investment?

August 3, 2024 | aaii.comA

Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

July 30, 2024 | globenewswire.com

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

June 24, 2024 | globenewswire.com

Panbela Therapeutics Inc. (PBLA) Insider Activity

May 25, 2024 | nasdaq.com

HC Wainwright & Co. Downgrades Panbela Therapeutics (PBLA)

May 17, 2024 | msn.com

Q1 2024 Panbela Therapeutics Inc Earnings Call

May 16, 2024 | uk.finance.yahoo.com

Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2024 Earnings Call Transcript

May 16, 2024 | msn.com

Panbela Therapeutics Inc (PBLA) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...

May 16, 2024 | finance.yahoo.com

Panbela Provides Business Update and Reports Q1 2024 Financial Results

May 15, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BON, BPTH, PBLA, and HEPA Company Descriptions

Bon Natural Life NYSE:BON

$1.41 +0.02 (+1.44%)

Closing price 03:53 PM Eastern

Extended Trading

$1.40 -0.01 (-1.06%)

As of 04:59 PM Eastern

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.

Bio-Path NASDAQ:BPTH

$0.12 +0.02 (+23.27%)

As of 03:58 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Hepion Pharmaceuticals NASDAQ:HEPA

$0.08 +0.02 (+25.59%)

As of 03:27 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Panbela Therapeutics NASDAQ:PBLA

$0.16 0.00 (0.00%)

As of 10:47 AM Eastern

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time